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G-H-1
DONOR LYMPHOCYTE INFUSION (DLI) FOR LEUKEMIA RELAPSE: A revisit
W.Y. Au. A.K.W. Lie, Y.L. Kwong, C.K. Lee, C.S. Chim, Y.H. Leung, R. Liang. Department of Medicine, Queen
Mary Hospital, Hong Kong
Background: The curative effect of bone marrow transplantation (BMT) is partly due to the graft versus leukemia
effect. This can be augmented by DLI at leukemia relapse and induce sustained remissions.
Method: From 9/95-8/99, 18 cases (10 chronic myeloid leukemia (CML), 3 acute myeloid leukemia (AML), 4 acute
lymphoblastic leukemia (ALL), 1 atypical CML) were treated. Their median age was 33 (range 18-49). Peripheral
buffy coat (median 2.3 x 108/kg lymphocytes, range 0.13-12.2) apheresed from the previous donor was infused in 2
to 6 doses, with no graft versus host disease (GVHD) prophylaxis. For AML and ALL cases, chemotherapy was
added for initial disease control.
Results: The overall complete remission (CR) & partial remission (PR) rate was 13/18 (72%). 8/10 CML cases
(80%) achieved CR (including 6 molecular remissions), and 1 achieved near CR (90%Ph-ve). DLI induced molecular
CR in one AML case, while 2 cases (1AML, ALL) were maintained in PR with isolated extramedullary disease
(EMD). Both CML-BT and aCML cases did not respond. CR was not achieved in 4 cases relapsing <6month post
BMT. Notably 8/9 cases failing to achieve sustained CR have EMD components. The median time of follow up of
survivors was 22 mo, (range 1 to 48 mo.). The major side effects included self-limiting liver GVHD (n=5), severe
skin GVHD (n=2), and herpes zoster virus/ cytomegalovirus reactivation (n=4).
Conclusions: DLI is a valuable treatment option for patients relapsing after BMT. Factors predictive of a successful
response are: molecular relapse only, Ph+ve CML, relapse >1 year from BMT, no EMD, and preserved donor
chimerism.
G-H-2
Ex Vivo Expansion of Peripheral Blood Haematopoietic Stem Cells: Preclinical Studies.
M.F. Ang. A.K.W. Lie, J. Chan, R. Liang, Y.L. Kwong. Department of Medicine, Queen Mary Hospital, Hong
Kong.
Introduction. In autologous peripheral blood haematopoietic stem cell transplantation (aBMT), a period of severe
neutropenia inevitably develops, owing to a deficiency of committed myeloid precursors that can give rise to mature
neutrophils. Therefore, a combination of haematopoietic stem cells and more committed myeloid progenitor cells
may overcome this problem, with the early haematopoietic recovery being mediated by more committed progenitors,
and the long term haematopoiesis being maintained by repopulation with pluripotential stem cells. To test this
hypothesis, we conducted preclinical studies to examine the expansion ex vivo of peripheral blood haematopoietic
stem cells. Materials and methods. Circulating haematopoietic stem cells were collected with informed consent
from patients undergoing stem cell mobilisation for aBMT. CD34 positive cells were isolated by positive selection
with immunomagnetic beads coated with a monoclonal anti-CD34 antibody. The purity was verified by flow
cytometry. Purified CD34 cells were plated at a concentration of 5,000 cells/ml/well, 10,000 cells/ml/well, and
20,000 cells/ml/well, in a stroma free suspension culture, supplemented with the haematopoietic growth factors
interleukin-3 (IL-3), IL-6, stem cell factor, granulocyte colony stimulating factor, stem cell factor, and megakaryocytes
growth and development factor, for 12-14 days. Parameters measured included the percentage increase in cell
numbers, serial changes in surface antigen expression as defined by dual colour flow cytometric analysis, and
clonogenic assays. Results. 4 cases were investigated. Cell number increased gradually until day 7, when dramatic
increases in the rate of cell growth were observed (a mean increase of 90.8 fold at day 10). It was also observed that
the fold increase of cells in cultures initiated with 5,000 cells/ml was higher than cultures initiated with 20,000
cells/ml. The number of granulocyte-macrohage colony-forming units (CFU-GM) paralleled nucleated cell
production, peaking at day 10. Dual colour flow cytometry using antibodies to CD34, CD15, and CD11b evaluated
the distribution and maturation stages of cells during culture. From days 9-14 there was emergence of a CD15+
CD11b+ population, indicating the maturation of cultured cells toward more mature neutrophilic forms. This was
paralleled by a decrease of CD34+ cells, which dropped to only 1.6% of the starting number by day 14. Conclusion.
At the end of a 14-day culture, cells produced were predominantly neutrophil precursors, and were developing
normally as assessed by immunophenotype and CFU-GM assay. The results suggest that ex vivo expansion of
haematopoietic stem cells could generate sufficient number of progenitors as a supplement to stem cell transplantation.
